Want to see HK:1877 full AI Analyst Report?
Top Page
Shanghai Junshi Biosciences Co., Ltd. Class H
(1877)
Select Model
Select Model
Rating:46Neutral
Price Target:
HK$19.00
â–¼(-31.01% Downside)
Action:Reiterated
Date:08/28/26
The score is held down primarily by weak financial quality: ongoing losses, significant negative free cash flow, and a sharp rise in leverage despite improving revenue and strong gross margins. Technicals provide modest support in the short term (above 20D/50D with neutral momentum), but the longer-term trend remains below key moving averages. Valuation is constrained by a negative P/E and no dividend yield data.
Positive Factors
Revenue Growth
Sustained revenue growth indicates improving commercial adoption of the company’s medicines and expanding demand. Continued top-line momentum can provide greater operating leverage as the portfolio scales and commercialization investments mature.
Negative Factors
Persistent Operating Losses
Ongoing operating and net losses show that strong product-level margins are not yet covering research, development, commercialization, and corporate costs. Persistent losses delay self-funded growth and leave profitability dependent on further scale or cost reductions.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Sustained revenue growth indicates improving commercial adoption of the company’s medicines and expanding demand. Continued top-line momentum can provide greater operating leverage as the portfolio scales and commercialization investments mature.
Read all positive factors
Shanghai Junshi Biosciences Co., Ltd. Class H (1877) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$33.87B
Dividend YieldN/A
Average Volume (3M)2.92M
Price to Earnings (P/E)―
Beta (1Y)1.54
Revenue Growth34.83%
EPS Growth58.94%
CountryHK
Employees2,903
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.40
Shares Outstanding260,295,700
10 Day Avg. Volume2,993,960
30 Day Avg. Volume2,915,028
Financial Highlights & Ratios
PEG Ratio0.64
Price to Book (P/B)3.19
Price to Sales (P/S)7.92
P/FCF Ratio-15.87
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$25.65Price Target Upside-6.87% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.12
Revenue Forecast (FY)HK$3.42B
Shanghai Junshi Biosciences Co., Ltd. Class H Business Overview & Revenue Model
Company Description
Shanghai Junshi Biosciences Co., Ltd. is a biopharmaceutical firm focused on the research, creation, and marketing of diverse pharmaceutical products. Operating within the People's Republic of China, its therapeutic focus spans oncology, metabolic...
How the Company Makes Money
The company primarily makes money through (1) product sales of its commercialized medicines, where revenue is generated from selling approved drugs into end markets via its own commercialization capabilities and/or distribution channels; (2) licen...
Shanghai Junshi Biosciences Co., Ltd. Class H Financial Statement Overview
Summary
Income Statement
46
Neutral
Balance Sheet
50
Neutral
Cash Flow
33
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.01B | 2.43B | 1.95B | 1.50B | 1.45B | 4.02B |
| Gross Profit | 2.39B | 1.97B | 1.54B | 835.26M | 927.21M | 2.77B |
| EBITDA | -363.35M | -599.38M | -935.50M | -2.16B | -2.52B | -476.32M |
| Net Income | -435.91M | -851.76M | -1.28B | -2.28B | -2.39B | -718.56M |
Balance Sheet | ||||||
| Total Assets | 14.25B | 12.39B | 10.80B | 11.36B | 12.58B | 11.05B |
| Cash, Cash Equivalents and Short-Term Investments | 3.70B | 3.22B | 2.93B | 3.78B | 6.00B | 3.50B |
| Total Debt | 5.91B | 4.14B | 2.93B | 1.79B | 1.32B | 628.20M |
| Total Liabilities | 7.95B | 6.16B | 4.85B | 4.02B | 2.78B | 2.72B |
| Stockholders Equity | 5.94B | 6.03B | 5.86B | 7.17B | 9.50B | 7.96B |
Cash Flow | ||||||
| Free Cash Flow | -1.01B | -1.21B | -2.12B | -2.85B | -2.17B | -1.53B |
| Operating Cash Flow | -214.54M | -465.77M | -1.43B | -2.01B | -1.78B | -641.90M |
| Investing Cash Flow | -2.51B | -1.58B | -892.78M | -892.42M | -467.62M | -1.88B |
| Financing Cash Flow | 2.52B | 2.17B | 1.02B | 681.04M | 4.64B | 2.67B |
Shanghai Junshi Biosciences Co., Ltd. Class H Technical Analysis
Negative
27.54
Price Trends
18.77
Negative
20.25
Negative
21.48
Negative
Market Momentum
-0.28
Positive
43.84
Neutral
20.58
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1877, the sentiment is Negative. The current price of 27.54 is above the 20-day moving average (MA) of 18.72, above the 50-day MA of 18.77, and above the 200-day MA of 21.48, indicating a bearish trend. The MACD of -0.28 indicates Positive momentum. The RSI at 43.84 is Neutral, neither overbought nor oversold. The STOCH value of 20.58 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1877.
Shanghai Junshi Biosciences Co., Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | HK$67.05B | 11.82 | 128.12% | ― | 305.94% | ― | |
64 Neutral | HK$35.74B | 35.47 | 20.41% | ― | 32.63% | 8.87% | |
63 Neutral | HK$176.65B | 121.12 | 6.06% | ― | 42.64% | 9.67% | |
52 Neutral | HK$22.80B | -14.63 | -27.40% | ― | 5.38% | 16.86% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | HK$88.43B | -79.15 | -10.86% | ― | 42.47% | -15.80% | |
46 Neutral | HK$33.87B | -76.96 | -7.32% | ― | 34.83% | 58.94% |
* Healthcare Sector Average
HK:1877
Shanghai Junshi Biosciences Co., Ltd. Class H
17.64
-17.28
-49.48%
HK:1801
Innovent Biologics
98.20
-1.40
-1.41%
HK:9688
Zai Lab Ltd
20.00
-4.60
-18.70%
HK:9926
Akeso, Inc.
95.05
-38.45
-28.80%
HK:9995
RemeGen Co. Ltd. Class H
77.25
-24.15
-23.82%
HK:2696
Shanghai Henlius Biotech, Inc. Class H
67.20
-13.90
-17.14%
Shanghai Junshi Biosciences Co., Ltd. Class H Corporate Events
Junshi Biosciences Board Approves 2026 Interim Report at Fully Attended Meeting
Aug 26, 2026
Shanghai Junshi Biosciences announced that its board of directors held the twenty-second meeting of the fourth session on 26 August 2026, with all 14 directors attending either on-site or via correspondence. The company confirmed that the meeting ...
Shanghai Junshi Biosciences Ends 2026 Employee Stock Ownership Scheme
Aug 26, 2026
Shanghai Junshi Biosciences Co., Ltd. is a biopharmaceutical company based in the People’s Republic of China and listed in Hong Kong. The company develops and commercializes innovative medicines, with a focus on sustaining long-term growth t...
Shanghai Junshi Biosciences Boosts Revenue, Returns to Profit on TUOYI Growth and Strong Financing
Aug 26, 2026
Shanghai Junshi Biosciences reported interim results for the six months ended 30 June 2026 showing strong top-line growth driven by its core immuno-oncology drug TUOYI and higher out-licensing revenue. The company maintained substantial investment...
Shanghai Junshi Biosciences Completes RMB0.7 Billion Technology Innovation Bond Issuance
Aug 21, 2026
Shanghai Junshi Biosciences has completed the issuance of its 2026 third tranche of technology innovation bonds, raising RMB0.7 billion in three-year notes at an interest rate of 2.55%. The funds were received on 21 August 2026, with the bonds set...
Junshi Biosciences Details Stake Reduction by Key Pre-IPO Shareholder
Aug 19, 2026
Shanghai Junshi Biosciences announced the completion of a shareholding reduction by substantial shareholder Shanghai Tanying Investment Partnership, which previously held 59,459,326 A shares, or 5.79% of the company’s total share capital. Th...
Junshi Biosciences Sets August Board Meeting to Approve Interim 2026 Results
Aug 12, 2026
Shanghai Junshi Biosciences Co., Ltd. has scheduled a board meeting for 26 August 2026 to review and approve the group’s interim financial results for the six months ended 30 June 2026. The session may also address other corporate matters, u...
Junshi Biosciences Discloses Reduction in Major Shareholder’s Equity Stake
Aug 10, 2026
Shanghai Junshi Biosciences reported a change in equity holdings by major shareholder Shanghai Tanying Investment Partnership and its concerted parties, Loyal Valley Capital Advantage Fund II and LVC Renaissance Fund. Their combined stake in the c...
Shanghai Junshi Biosciences Reports Completion of Shareholder’s Stake Reduction
Aug 10, 2026
Shanghai Junshi Biosciences has disclosed the outcome of a shareholding reduction by substantial shareholder He Ming, who previously held 3,531,380 A shares, representing 0.3440% of the company’s total share capital. These shares were largel...
Junshi Biosciences Shareholders Approve H-Share Buyback Mandate
Jul 27, 2026
Shanghai Junshi Biosciences Co., Ltd., a Hong Kong-listed biopharmaceutical producer of innovative therapies, maintains a dual listing through A shares in mainland China and H shares in Hong Kong. Its capital structure includes more than 1.02 bill...
Junshi Biosciences Completes RMB300 Million Technology Innovation Bond Issuance
Jul 22, 2026
Shanghai Junshi Biosciences has completed the issuance of its 2026 second tranche of technology innovation bonds, raising RMB0.3 billion with a three-year term and a 2.59% coupon, maturing on July 22, 2029. The funds were received on July 22, 2026...
Junshi Biosciences Wins NMPA Nod to Expand Toripalimab Use in Early-Stage Lung Cancer
Jul 21, 2026
Shanghai Junshi Biosciences has received acceptance from China’s National Medical Products Administration for a supplemental application to expand the approved indication of its PD-1 inhibitor toripalimab (TUOYI). The revision seeks to use t...
Junshi Biosciences Calls EGM to Seek Mandate for H-Share Buyback
Jul 8, 2026
Shanghai Junshi Biosciences has called its first extraordinary general meeting of 2026 for July 27 in Shanghai, inviting holders of its H shares to vote on a special resolution granting the board a general mandate to repurchase the company’s...
Junshi Biosciences Sets H Share Register Closure Ahead of July EGM
Jul 8, 2026
Shanghai Junshi Biosciences Co., Ltd. has announced that the register of members of its H shares will be closed from 22 July 2026 to 27 July 2026, inclusive, with no share transfers registered during that period. The move is designed to determine ...
Junshi Biosciences Licenses Autoimmune Antibody Roconkibart to Fosun Wanbang for Greater China
Jul 1, 2026
Shanghai Junshi Biosciences has signed a licensing agreement with Fosun Wanbang, a subsidiary of Fosun Pharma, granting it exclusive rights to develop, register and commercialize the anti-IL-17A monoclonal antibody roconkibart (JS005) in Greater C...
Junshi Biosciences Details Valuation Basis for Assets in Joint Venture
Jun 26, 2026
Shanghai Junshi Biosciences has issued a supplemental announcement detailing the valuation methodology for assets contributed to a newly formed joint venture company under a connected transaction. The move clarifies how the company is pricing its ...
Shanghai Junshi Biosciences Shareholders Approve All Resolutions at 2025 AGM
Jun 26, 2026
Shanghai Junshi Biosciences Co., Ltd. reported the poll results of its 2025 annual general meeting in Shanghai, where all proposed resolutions were approved by shareholders. Attendance covered both A and H share classes, with nearly 30% of eligibl...
Shanghai Junshi Biosciences Restructures Board Roles and Governance Committees
Jun 26, 2026
Shanghai Junshi Biosciences has updated the composition of its board of directors, detailing a leadership structure that includes a chairman, vice chairman, co-chief executive officer and several executive, non-executive and independent non-execut...
Shanghai Junshi Biosciences reshapes board and committees to bolster governance
Jun 26, 2026
Shanghai Junshi Biosciences has strengthened its board structure with the election of Chen Liang as an independent non-executive director, effective June 26, 2026, following shareholder approval at the annual general meeting. His appointment, gove...
Junshi Biosciences Discloses Equity Reduction by Major Shareholder Group
Jun 15, 2026
Shanghai Junshi Biosciences Co., Ltd. announced changes in the shareholding of major investor Shanghai Tanying Investment Partnership (LP) and its concerted parties, which collectively reduced their equity stake in the company. Following the trans...
Shanghai Junshi Biosciences Sets Up Connected JV to House Key IP Assets
Jun 5, 2026
Shanghai Junshi Biosciences plans to form a joint venture with Suzhou Union, Junshi Biotechnology, Suzhou Junmeng, a JV company and non-executive director Dr. Yao, contributing licensed intellectual property, tangible assets and related IP rights....
Shanghai Junshi Biosciences Calls 2025 AGM and Seeks Mandate for RMB 2.5 Billion Debt Issuance
Jun 5, 2026
Shanghai Junshi Biosciences has called its 2025 annual general meeting for 26 June 2026 in Shanghai to seek shareholder approval on a wide range of corporate matters, including the 2025 annual report, profit distribution plan, dividend policy for ...
Shanghai Junshi Biosciences Sets H Share Register Closure for 2025 AGM
Jun 5, 2026
Shanghai Junshi Biosciences has announced the closure of its H share register from 23 June 2026 to 26 June 2026, during which no transfers of H shares will be processed. This measure is to determine which H share investors are entitled to attend a...
Shanghai Junshi Biosciences Reassigns Dr. Yao Sheng to Non-Executive Director Role
Jun 5, 2026
Shanghai Junshi Biosciences announced that Dr. Yao Sheng has resigned as deputy general manager and as a director of its subsidiary Suzhou Junao Precision Medicine due to other work arrangements, and has been re-designated from an executive direct...
Junshi Biosciences Sets Out Board Composition and Committee Roles
Jun 5, 2026
Shanghai Junshi Biosciences has detailed the composition of its board of directors, listing a mix of executive, non-executive and independent non-executive members, including a chairman, vice chairman and co-chief executive officers. The disclosur...
Junshi Biosciences Reshapes Ownership of Key R&D Subsidiary Without Changing Fund Use
Jun 5, 2026
Shanghai Junshi Biosciences has announced changes to the shareholding structure of its subsidiary Ningbo Junyan Hongshi Biomedical Technology, which serves as an implementing entity for certain innovative drug RD sub-projects financed by its 2022 ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.